GO:0000340 RNA 7-methylguanosine cap binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000340 (RNA 7-methylguanosine cap binding) describes the molecular function of selectively binding the m7G cap added cotranscriptionally to the 5' end of RNA polymerase II transcripts.
• The cap-binding complex (CBC), composed of NCBP1 (CBP80) and NCBP2 (CBP20), is the canonical m7G cap-binding factor and couples capping to splicing, export, and translation.
• Additional m7G cap readers include eIF4E/eIF4G for translation initiation, gemin5 in the SMN complex, and QKI for internal m7G-modified transcripts.
• m7G cap recognition is a validated node in gene expression control, influencing mRNA stability, translation efficiency, and stress responses.
• Dysregulation of cap-binding proteins is implicated in cancer, neurodegeneration, and stem cell differentiation, making them attractive therapeutic targets.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of cap-binding protein function in disease and development.
Description
RNA 7-methylguanosine cap binding (GO:0000340) is the molecular function of recognizing and binding the m7G cap structure that is added cotranscriptionally to the 5' end of RNA polymerase II transcripts. This cap is a hallmark of eukaryotic mRNAs and many non-coding RNAs, and its recognition by dedicated proteins is essential for mRNA processing, export, translation, and turnover. The cap-binding complex (CBC), a heterodimer of NCBP1 and NCBP2, was the first identified m7G cap-binding factor and remains the central hub for cap-dependent gene regulation. Beyond the CBC, other proteins such as eIF4E, gemin5, and QKI have been shown to bind the m7G cap or internal m7G modifications, expanding the functional repertoire of this ontology term. Researchers study GO:0000340 to understand how cells interpret the 5' end of transcripts, how this process is hijacked in disease, and how it can be targeted therapeutically.
RNA 7-methylguanosine cap binding At A Glance
| GO ID | GO:0000340 |
|---|---|
| GO term | RNA 7-methylguanosine cap binding |
| Ontology | molecular_function |
| Synonym | RNA m7G cap binding |
| Definition | Binding to a 7-methylguanosine group added cotranscriptionally to the 5' end of RNA molecules transcribed by polymerase II |
| Major function | Recognition of the m7G cap on RNA polymerase II transcripts, enabling downstream processing, export, translation, and stability |
| Representative proteins | NCBP1, NCBP2, EIF4E, GEMIN5, QKI |
| Cellular context | Nucleus (capping, splicing, export) and cytoplasm (translation, decay, stress granules) |
| Disease relevance | Cancer, neurodegeneration, stem cell differentiation, and ribosomopathies |
What Is GO:0000340?
GO:0000340 is defined by QuickGO as the binding to a 7-methylguanosine group added cotranscriptionally to the 5' end of RNA molecules transcribed by polymerase II. In other words, it is the selective molecular recognition of the m7G cap structure on RNA, a function carried out by specialized cap-binding proteins that discriminate the methylated cap from other RNA ends.
Why Is RNA 7-methylguanosine cap binding Important in Cell Biology?
RNA 7-methylguanosine cap binding is a central node in post-transcriptional gene regulation because the m7G cap is the first modification on every RNA polymerase II transcript and serves as a platform for recruiting the machinery that controls RNA fate. Defects in cap-binding proteins lead to misregulated splicing, export, and translation, which are linked to cancer, neurodegeneration, and developmental disorders. Understanding this function is therefore critical for basic RNA biology and for therapeutic development targeting cap-dependent processes.
• The m7G cap is a universal mark of RNA polymerase II transcripts, and its binding is the first step in mRNA quality control.
• Cap-binding complex (CBC) couples capping to splicing and export, influencing transcript isoform diversity.
• eIF4E binding to the cap is rate-limiting for cap-dependent translation initiation.
• Gemin5 binds the m7G cap and links it to SMN complex function and RNA metabolism.
• QKI binds internal m7G-modified transcripts and modulates mRNA metabolism and stress granule dynamics.
• Dysregulated cap binding is observed in cancer, where Myc-driven transcription increases capping demand.
• Stem cell differentiation and stress responses involve a switch between IRES and cap-initiated translation.
• Cap-binding proteins are potential drug targets for antiviral and anticancer therapies.
• Multicapped mRNA and capped circular RNA designs exploit cap-binding mechanisms to augment translation.
• CRISPR screens can identify novel cap-binding regulators and their disease relevance.
Molecular Mechanism of RNA 7-methylguanosine cap binding
Recognition of the m7G cap by the CBC
In simple terms: The cap-binding complex grabs the methylated cap at the start of an RNA and holds it to help the RNA be processed and exported.
The cap-binding complex (CBC) is a heterodimer of NCBP1 (CBP80) and NCBP2 (CBP20) that specifically binds the m7G cap on RNA polymerase II transcripts. Structural and biochemical studies show that NCBP2 inserts aromatic residues into the cap-binding pocket to stack against the methylated guanine, while NCBP1 stabilizes the complex and recruits downstream factors. This binding occurs cotranscriptionally and is required for efficient splicing and nuclear export of capped RNAs.
Cap-dependent translation initiation by eIF4E
In simple terms: In the cytoplasm, eIF4E grabs the cap to start protein synthesis.
eIF4E is the cytoplasmic cap-binding protein that recognizes the m7G cap and, together with eIF4G and eIF4A, assembles the translation initiation complex on the 5' end of mRNA. The mechanism of mRNA cap recognition by eIF4E involves a conserved tryptophan-rich pocket that sandwiches the methylated guanine, and this interaction is a key regulatory step for translation initiation. Recent studies have elucidated how eIF4E distinguishes the cap from other RNA ends and how this is coupled to mRNA activation.
Non-canonical cap readers: gemin5 and QKI
In simple terms: Other proteins can also bind the cap or internal m7G marks to control RNA fate.
Gemin5 was identified as a novel 7-methylguanosine cap-binding protein that associates with the SMN complex and regulates RNA metabolism. QKI, an RNA-binding protein, shuttles internal m7G-modified transcripts into stress granules and modulates mRNA metabolism, demonstrating that m7G cap binding is not limited to the 5' end. These non-canonical readers expand the functional scope of GO:0000340 beyond translation initiation.
Regulation by cellular signals and stress
In simple terms: Cell signals and stress can change how cap binding works, switching translation modes.
Cap-dependent translation is regulated by signaling pathways such as mTOR, which controls eIF4E availability through 4E-BP phosphorylation. During stress, cells can switch from cap-initiated to IRES-mediated translation, as observed during stem cell differentiation and stress responses. This plasticity highlights that cap binding is dynamically regulated rather than constitutive.
Engineered cap structures and therapeutic implications
In simple terms: Scientists can design special caps to improve RNA medicines.
Chemical and topological design of multicapped mRNA and capped circular RNA has been shown to augment translation, leveraging cap-binding mechanisms for therapeutic benefit. These engineered caps enhance translation efficiency and stability, demonstrating the translational potential of understanding GO:0000340. Such approaches are being explored for vaccine and protein replacement applications.
Key Genes Involved in GO:0000340 RNA 7-methylguanosine cap binding
The following genes encode proteins that directly or indirectly mediate RNA 7-methylguanosine cap binding and its downstream functions.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NCBP1 | Core subunit of the cap-binding complex (CBC) | Essential for splicing, export, and cap-dependent processes; knockout is lethal in many models |
| NCBP2 | Cap-binding subunit of CBC that directly contacts m7G | Key for cap recognition; point mutations alter cap affinity |
| EIF4E | Cytoplasmic cap-binding protein for translation initiation | Oncogene and drug target; regulates translation of growth factors |
| EIF4G | Scaffold that binds eIF4E and ribosome | Integrates cap binding with translation initiation |
| GEMIN5 | Non-canonical m7G cap-binding protein in SMN complex | Links cap binding to RNA metabolism and neurodegeneration |
| QKI | Binds internal m7G-modified transcripts | Modulates mRNA metabolism and stress granules |
| SMN1 | Survival motor neuron protein, interacts with gemin5 | Spinal muscular atrophy; cap-binding complex partner |
| MYC | Transcription factor that drives capping demand | Oncogene; links transcription to mRNA capping |
| EIF4EBP1 | Repressor of eIF4E cap binding | Regulated by mTOR; controls translation initiation |
| EIF4A1 | RNA helicase in translation initiation | Works with eIF4E/eIF4G at the cap |
| NCBP3 | Auxiliary cap-binding complex subunit | Modulates CBC function in RNA processing |
| PHAX | Adaptor for CBC-dependent export | Required for snRNA and mRNA export |
| ALYREF | Export adaptor that binds CBC | Couples cap binding to nuclear export |
| DDX3X | RNA helicase involved in translation and stress granules | Interacts with cap-binding machinery |
| G3BP1 | Stress granule marker that interacts with QKI | Links m7G metabolism to stress response |
| EIF4E2 | Cap-binding protein for hypoxia-induced translation | Alternative cap reader under stress |
| EIF4E3 | Cap-binding protein with tissue-specific roles | Potential tumor suppressor |
| LARP1 | Binds cap and regulates TOP mRNA translation | mTOR-dependent translation control |
How Is RNA 7-methylguanosine cap binding Regulated?
RNA 7-methylguanosine cap binding is regulated at multiple levels. The availability of eIF4E is controlled by mTOR signaling through phosphorylation of 4E-BP proteins, which release eIF4E to bind the cap. Cellular stress can switch translation from cap-dependent to IRES-mediated modes, as seen during stem cell differentiation and stress responses. Additionally, the expression and post-translational modification of CBC subunits and non-canonical readers like QKI and gemin5 modulate cap-binding activity in response to developmental and environmental cues.
RNA 7-methylguanosine cap binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EIF4E | Cancer (oncogene, translation dysregulation) | Knockout and overexpression in cancer cell lines; xenograft models |
| GEMIN5 | Spinal muscular atrophy, neurodegeneration | Point mutations in iPSC-derived motor neurons; KO mice |
| QKI | Stress granule-related neurodegeneration | Knockout and tagged knock-in in neuronal cells; stress induction |
| NCBP1/NCBP2 | Developmental disorders, splicing defects | Conditional knockout in mouse models; patient-derived fibroblasts |
| MYC | Cancer (transcription-capping axis) | Overexpression and knockout in lymphoma models |
Cancer
Dysregulated cap-dependent translation is a hallmark of many cancers. eIF4E is overexpressed in various tumors and promotes translation of oncogenic mRNAs, while Myc-driven transcription increases the demand for mRNA capping. Targeting cap-binding proteins or their regulators is an active therapeutic strategy.
Neurodegeneration and ribosomopathies
Gemin5, a cap-binding protein, is part of the SMN complex, and its dysfunction is linked to spinal muscular atrophy and other neurodegenerative conditions. QKI-mediated m7G metabolism is also implicated in stress granule dynamics, which are relevant to amyotrophic lateral sclerosis and related disorders.
Stem cell differentiation and stress responses
A shift between IRES and cap-initiated translation occurs during homeostatic stem cell differentiation and stress, highlighting the role of cap binding in cell fate decisions. This has implications for regenerative medicine and cancer stem cell biology.
From RNA 7-methylguanosine cap binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of cap-binding protein affect translation? | CRISPR knockout of EIF4E or NCBP2 followed by polysome profiling |
| How do point mutations in the cap-binding pocket alter affinity? | Point-mutation knock-in of NCBP2 or EIF4E in cell lines |
| Can tagged cap-binding proteins be used for interactomics? | Knock-in of FLAG/HA tags at endogenous loci |
| Does overexpression of eIF4E drive oncogenic translation? | Overexpression models in cancer cell lines and mouse models |
| How does QKI regulate internal m7G transcripts? | Knockout and rescue with wild-type or mutant QKI |
| What is the role of gemin5 in SMN complex function? | Knockout and point mutations in iPSC-derived neurons |
How to Study the RNA 7-methylguanosine cap binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Genome-wide translation efficiency | Assessing cap-dependent translation changes |
| RNA-seq | Transcript abundance and splicing | Identifying CBC-dependent splicing events |
| m7G-seq | Mapping of m7G modifications | Detecting internal m7G on QKI targets |
| CLIP-seq | Protein-RNA binding sites | Mapping eIF4E or QKI binding across transcriptome |
| Mass spectrometry | Protein interactions and modifications | Identifying CBC interactors |
| Fluorescence microscopy | Subcellular localization | Visualizing stress granule recruitment |
| Polysome profiling | mRNA distribution in translation | Measuring cap-dependent initiation |
| CRISPR screens | Gene essentiality and modifiers | Identifying regulators of cap binding |
Ribosome profiling (Ribo-seq)
Ribo-seq measures translation efficiency genome-wide and can reveal how cap-binding perturbations alter the translatome. It is particularly useful for distinguishing cap-dependent from IRES-mediated translation.
RNA sequencing and m7G mapping
RNA-seq and specialized m7G mapping techniques (e.g., m7G-seq) identify transcripts with altered cap status and splicing upon cap-binding protein manipulation.
Proteomics and interactomics
Affinity purification coupled to mass spectrometry of tagged cap-binding proteins reveals dynamic interactomes and post-translational modifications.
Imaging and stress granule assays
Fluorescence microscopy of GFP-tagged cap-binding proteins and stress granule markers (e.g., G3BP1) visualizes localization changes under stress.
How CRISPR Can Be Used to Study GO:0000340 RNA 7-methylguanosine cap binding
Knockout
CRISPR knockout of cap-binding genes such as NCBP1, NCBP2, or EIF4E can reveal their essentiality and impact on translation, splicing, and cell viability. Conditional knockout models allow tissue-specific studies.
Point Mutation
Point mutations in the cap-binding pocket (e.g., in NCBP2 or EIF4E) can dissect the contribution of cap binding versus other functions, providing mechanistic insights.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) at endogenous loci enables proteomic and imaging studies of cap-binding proteins under native regulation.
Overexpression
Overexpression of eIF4E or QKI can model oncogenic or stress-related states and test sufficiency in driving translation or stress granule phenotypes.
How EDITGENE Supports RNA 7-methylguanosine cap binding Research
Researchers studying RNA 7-methylguanosine cap binding-related genes often need to determine whether a candidate gene is causally involved in a specific RNA processing or translation phenotype. EDITGENE provides the CRISPR tools and services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for RNA 7-methylguanosine cap binding research.
Frequently Asked Questions About RNA 7-methylguanosine cap binding
What is RNA 7-methylguanosine cap binding?
It is the molecular function (GO:0000340) of selectively binding the m7G cap added to the 5' end of RNA polymerase II transcripts, carried out by proteins such as the cap-binding complex.
What genes are involved in RNA 7-methylguanosine cap binding?
Key genes include NCBP1, NCBP2, EIF4E, GEMIN5, and QKI, among others.
What is the cap-binding complex (CBC)?
The CBC is a heterodimer of NCBP1 and NCBP2 that binds the m7G cap and couples it to splicing and export.
How does eIF4E recognize the m7G cap?
eIF4E uses a conserved tryptophan-rich pocket to stack against the methylated guanine, initiating cap-dependent translation.
What diseases are linked to cap-binding proteins?
Cancer, neurodegeneration, spinal muscular atrophy, and stem cell differentiation disorders are linked to dysregulated cap binding.
How can I study RNA 7-methylguanosine cap binding?
Methods include Ribo-seq, RNA-seq, m7G-seq, CLIP-seq, proteomics, and CRISPR screens.
What is the role of QKI in m7G cap binding?
QKI binds internal m7G-modified transcripts and shuttles them into stress granules, modulating mRNA metabolism.
Is gemin5 a cap-binding protein?
Yes, gemin5 was identified as a novel 7-methylguanosine cap-binding protein in the SMN complex.
Can cap binding be targeted therapeutically?
Engineered multicapped mRNA and capped circular RNA exploit cap-binding mechanisms to augment translation, showing therapeutic potential.
What CRISPR models are available for cap-binding research?
EDITGENE offers knockout, point-mutation, knock-in, overexpression, and library screening services for cap-binding genes.
Conclusion
RNA 7-methylguanosine cap binding (GO:0000340) is a fundamental molecular function that governs the fate of RNA polymerase II transcripts from synthesis to translation. The cap-binding complex, eIF4E, gemin5, and QKI represent key readers that link cap recognition to splicing, export, translation, and stress responses. Dysregulation of these processes contributes to cancer, neurodegeneration, and developmental disorders, making them important research and therapeutic targets. Advanced CRISPR models and multi-omics methods continue to illuminate the mechanistic details and disease relevance of this essential function.
References
- 1. Zhao Z et al.. 2023. QKI shuttles internal m(7)G-modified transcripts into stress granules and modulates mRNA metabolism.. Cell 186(15):3208-3226.e27 PMID: 37379838
- 2. Chen H et al.. 2025. Chemical and topological design of multicapped mRNA and capped circular RNA to augment translation.. Nat Biotechnol 43(7):1128-1143 PMID: 39313647
- 3. Gonatopoulos-Pournatzis T et al.. 2014. Cap-binding complex (CBC).. Biochem J 457(2):231-42 PMID: 24354960
- 4. Bradrick SS et al.. 2009. Identification of gemin5 as a novel 7-methylguanosine cap-binding protein.. PLoS One 4(9):e7030 PMID: 19750007
- 5. Gentry RC et al.. 2025. The mechanism of mRNA cap recognition.. Nature 637(8046):736-743 PMID: 39663447
- 6. Gentry RC et al.. 2023. The mechanism of mRNA activation.. bioRxiv PMID: 38014128
- 7. Dunn S et al.. 2015. Myc and mRNA capping.. Biochim Biophys Acta 1849(5):501-5 PMID: 24681440
- 8. Mazzola MC et al.. 2026. Shifting IRES versus Cap-initiated translation during homeostatic stem cell differentiation and stress.. Sci Adv 12(21):eadz7896 PMID: 42172329
